(Total Views: 845)
Posted On: 01/10/2023 1:53:55 PM
Post# of 148872
Denis Burger is a Professor at University of Oregon Health Sciences Center. He was CEO/President of a small Corvallis, OR Biotech named AVII from mid 1990s until 2007 when he resigned all duties for unclear reasons. AVII was a penny stock for several years and eventually changed its name to SRPT. With a new CEO who didn't antagonize the FDA and its new name and with Janet Woodcock's help SRPT's drug for Duchenne Muscular dystrophy was OKed.. The share price then peaked at around 170/share and has been anywhere from 75 to 160 since.
I really like the similarities between SRPT and CYDY as CYDY is following the successful script that SRPT used. A new name and new CEO that will be taken seriously by the FDA. Leronlimab appears to be a much better and way more versatile drug than SRPT's drug. Needless to say I have hundreds of thousands of CYDY shares waiting for the wheels to turn.
Good science + Good management = very good share price returns for CYDY or whatever the new name will be.
I really like the similarities between SRPT and CYDY as CYDY is following the successful script that SRPT used. A new name and new CEO that will be taken seriously by the FDA. Leronlimab appears to be a much better and way more versatile drug than SRPT's drug. Needless to say I have hundreds of thousands of CYDY shares waiting for the wheels to turn.
Good science + Good management = very good share price returns for CYDY or whatever the new name will be.
(14)
(0)Scroll down for more posts ▼
